Psoriasis Serum

Human Psoriasis Serum for Immune-Mediated Inflammatory Disease Research

Our Psoriasis Serum is sourced from IRB-consented donors clinically diagnosed with psoriasis. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for characterising the systemic inflammation associated with psoriasis. Aliquot volumes are configured per project and reported per lot.

Why Serum for Psoriasis Research

Psoriasis is a chronic immune-mediated inflammatory disease. It is not classically autoimmune — there is no established defining autoantibody — and its pathology is driven by the IL-23 and IL-17 axis acting on keratinocytes. Serum is where the systemic dimension of that disease, and its well-documented comorbidity burden, becomes measurable.

• Psoriasis is accompanied by systemic inflammation, and acute phase reactants such as CRP track broadly with disease extent, making serum useful for severity and comorbidity-risk biomarker research.
• The disease carries an established association with cardiometabolic comorbidity and metabolic syndrome, so serum lipid, glycaemic, and inflammatory profiling supports research into that link rather than into skin pathology alone.
• Circulating IL-17A itself is often present at concentrations at or below the sensitivity of routine immunoassays in psoriasis, so serum studies are generally better designed around downstream and keratinocyte-derived mediators; direct IL-17 pathway readouts are more reliably obtained from lesional skin.
• Serum is the conventional matrix for therapeutic drug monitoring and anti-drug antibody detection, which makes psoriasis serum from biologic-treated donors directly relevant to immunogenicity assay development.
• Because the clot is removed during processing, serum is a lower-complexity protein matrix than plasma, reducing interference in many multiplex immunoassay and mass spectrometry workflows.
• Psoriasis and psoriatic arthritis overlap substantially, so serum from donors with and without joint involvement supports research into markers that identify arthritis risk before it becomes clinically apparent.

Donor Stratification Available

• Severity: documented PASI, body surface area, or Investigator Global Assessment where recorded
• Clinical phenotype: chronic plaque, guttate, inverse, pustular, or erythrodermic, including scalp, nail, and palmoplantar involvement
• Presence or absence of psoriatic arthritis
• Treatment status: topical therapy, phototherapy, conventional systemic agent, TNF inhibitor, IL-17 inhibitor, IL-23 inhibitor, TYK2 inhibitor, apremilast, or biologic-naive
• Age of onset (early or late), disease duration, and family history
• Body mass index, smoking status, and metabolic comorbidities where documented
• Matched healthy controls available, alongside comparator inflammatory skin disease cohorts

Product Features

• Collected from clinically confirmed psoriasis donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request
• Volumes and lot-specific processing details reported per lot

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy and infectious disease history
• Donor-reported medication and treatment history
• Severity and comorbidity data available upon request

Applications

• Biomarker discovery and validation for psoriasis severity and treatment response
• Serum cytokine, chemokine, and acute phase protein profiling
• Cardiometabolic comorbidity and systemic inflammation research
• Therapeutic drug monitoring and anti-drug antibody assay development for biologics
• Proteomic and metabolomic characterisation of immune-mediated inflammation
• Research into markers predicting progression to psoriatic arthritis
• Immunoassay development, calibration, and matrix effect testing
• Therapeutic candidate screening and validation with authentic patient matrix

Other Psoriasis Specimen Types

• Psoriasis Plasma
• Psoriasis Whole Blood
• Psoriasis PBMC
• Psoriasis Leukopak
• Psoriasis Skin Punch Biopsy
• Psoriasis Bulk Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Psoriasis serum is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other disease states and collection formats, visit our human serum page.